Across TCGA pan-cancer cohorts, RABIF Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RABIF data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RABIF Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RABIF expression acts as an unfavorable survival marker.

BLCA and LGG are the cancer types where RABIF Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.158	0.720	<.001	36	view →
LGG	DFS	Median	All	0.068	0.833	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: RABIF tumor-vs-normal RNA expression · all RABIF data types